ALLERGY THERAPEUTICS PLC

Business and Financial Review • Sep 4, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6741Q

Allergy Therapeutics PLC

04 September 2014

4 September 2014

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Shareholder update

Allergy Therapeutics plc (AIM: "AGY" or the "Company"), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that CFR Pharmaceutical SA ("CFR"), a company associated with the Weinstein family and the largest shareholder in Allergy Therapeutics, will release its interim results for the period ended 30 June 2014 on the 4 September 2014. In order that CFR can comply with its reporting requirements Allergy Therapeutics has made the following unaudited financial information below available to CFR.

Balance Sheet as at 31 March 2014

	£ '000
Total Non-Current Assets	14,426
Total Current Assets	18,219
Total Current Liabilities	(5,339)
Total Non-Current Liabilities	(6,436)
Total Equity	20,870

Consolidated Income Statement for the 6 months ended 31 March 2014

	£'000
Revenue	27,426
Profit after tax for the period	5,503

Items have the same meaning as disclosed in Allergy Therapeutics plc's accounts for the year ended 30 June 2013.

-Ends-

For further information

Allergy Therapeutics	+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
www.allergytherapeutics.com
Peel Hunt LLP	+44 (0) 20 7418 8900
James Steel / Clare Terlouw
FTI Consulting	+44 (0) 20 3727 1000
Simon Conway / Victoria Foster Mitchell / Mo Noonan

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination.  It has a growing business with expected revenue of £45.7million, before milestones and rebates and supported by a foreign exchange benefit of £2.3million, an increase of 14% on the previous year (2013:£39.9milllion) achieved mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUGUBPBUPCGMP